Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Present with moderate-to-severe chronic plaque psoriasis based on a diagnosis of chronic psoriasis for at least 6 months before baseline.~* Participants who are candidates for systemic therapy and who are naive to systemic treatment for psoriasis.~* Have a (PASI score \>10 or BSA \>10) and DLQI \>10 at screening and at baseline.~Exclusion Criteria:~* Have predominant pattern of pustular, erythrodermic, and/or guttate forms of psoriasis.~* Have received systemic nonbiologic psoriasis therapy.~* Have prior, concurrent, or recent use of ixekizumab or any other biological psoriasis therapy.~* Have any condition or contraindication as addressed in the local labeling for MTX or FAE.~* Presence of significant uncontrolled cerebro-cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neurologic, or neuropsychiatric disorders or abnormal laboratory values at screening.~* Have severe gastrointestinal disease, oral ulcer, or known, active gastrointestinal ulcer.~* Have had a serious infection or are immunocompromised.~* At screening, participants with significant, present, or early liver disease, e.g., explained by alcohol consumption or hepatic insufficiency.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ixekizumab (Type: EXPERIMENTAL): 160 milligrams (mg) ixekizumab given as two subcutaneous injections (SC) followed by 80 mg ixekizumab given SC every 2 weeks until week 12 and then 80 mg ixekizumab given SC every 4 weeks until week 24.~Extension Period: At week 24, participants have the option to continue ixekizumab treatment for up to 36 weeks.
- Fumaric Acid Esters (Type: ACTIVE_COMPARATOR): Starting dose of 105 mg FAE given orally followed by 215 mg FAE given orally 1 to 3 times per day until week 24.~Extension Period: At week 24, participants have the option to begin ixekizumab treatment for up to 36 weeks.
- Methotrexate (Type: ACTIVE_COMPARATOR): 7.5 mg starting dose up to 30 mg MTX given orally once a week until week 24.~Extension Period: At week 24, participants have the option to begin ixekizumab treatment for up to 36 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).